Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||FGFR2 - WAC|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - WAC||intrahepatic cholangiocarcinoma||predicted - sensitive||Futibatinib||Case Reports/Case Series||Actionable||In a Phase I trial, Futibatinib (TAS-120) treatment at a dose of 16mg led to a partial response in 42.1% (8/19) of patients with intrahepatic cholangiocarcinoma harboring FGF or FGFR alterations, including a partial response with a progression-free survival of 6.9 months and a duration of response of 4.2 months in a patient harboring FGFR2-WAC (PMID: 34551969; NCT02052778).||34551969|
|FGFR2 - WAC||cholangiocarcinoma||predicted - sensitive||Infigratinib||Case Reports/Case Series||Actionable||In a clinical case study, treatment with Truseltiq (infigratinib) resulted in a partial response in a patient with cholangiocarcinoma harboring an FGFR2-WAC fusion (PMID: 34250419).||34250419|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|